Try our corporate solution for free!

Gilead Science's remdesivir manufacturing projections 2020

Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in

Use Ask Statista Research Service

Release date

July 2020


United States

Survey time period

as of July 2020

Supplementary notes

Original manufacturing projections from January to May based on 11-vial treatment course. Projections through end of June based on average 7.78 vials per treatment course. Year-end projection based on average 6.25 vials per treatment course.
Figures reflect the cumulative amount of drug that Gilead expects to produce and are inclusive of supply allocated for clinical trials, compassionate use and expanded access programs, and any potential regulatory authorizations or approvals.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Coronavirus: the pharma and medtech response"

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.